Company Profile

Biosource International Inc
Profile last edited on: 5/15/2014      CAGE:       UEI:

Business Identifier: Life science assays, biologics and reagents to accelerate the creation of new drug therapies and medical diagnostic methods
Year Founded
1989
First Award
1997
Latest Award
1997
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

542 Flynn Road
Camarillo, CA 93012
   (805) 987-0086
   tech.support@biosource.com
   www.biosource.com
Location: Multiple
Congr. District: 26
County: Ventura

Public Profile

In October 2005, Bosource became part of Invitrogen. BioSource provides integrated solutions for functional genomics, proteomics, and drug discovery through a wide collection of proteins, antibodies, reagents, and assay development for immunology, signal transduction and multiplex screening. Their expertise is in cytokine and growth factor protein assays. BioSource International develops and makes enzyme-linked immunosorbent assay (ELISA) test kits and other products used in biomedical research worldwide. The company offers more than 1,700 immunological and molecular biological products used to diagnose and research such conditions as cancer, aging, arthritis, and AIDS. The company has more than 70 ELISA tests, which are used by researchers and scientists to detect and measure substances in biological fluids from humans, rodents, swine, and primates. The firm also offers a variety of reagents and other products -- bioactive proteins, monoclonal and polyclonal antibodies, DNA. Wholly owned subsidiary BioSource Europe is headquartered in Belgium.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : BIOI
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 1 NIH $99,905
Project Title: Luciferase System For Nucleic Acid Detection

Key People / Management

  Terrance Bieker -- President

  Barry M Shuman

Company News

There are no news available.